LOX-1: A male hormone-regulated scavenger receptor for atherosclerosis

Vascular Pharmacology

Volumn 59, Issue 5-6, 2013, Pages 138-143

  Gao, Song ^a   Geng, Yong Jian ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Castration; Inflammation; LOX 1; Testosterone

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTILIPEMIC AGENT; BERBERINE; CHOLESTEROL; CURCUMIN; DIPEPTIDYL CARBOXYPEPTIDASE; EPIGALLOCATECHIN GALLATE; ESTRADIOL; ESTROGEN RECEPTOR; FIBRINOGEN; GELATINASE A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESVERATROL; STRESS ACTIVATED PROTEIN KINASE; TANSHINONE IIA; TESTOSTERONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANDROGEN THERAPY; ANGINA PECTORIS; APOPTOSIS; ARTERY COMPLIANCE; ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOLOGICAL ACTIVITY; CASTRATION; CELL ADHESION; CELL AGING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DISEASE COURSE; DOWN REGULATION; ESTROGEN THERAPY; FAT MASS; GENE DELETION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INTERNALIZATION; INTRAABDOMINAL FAT; ISCHEMIC HEART DISEASE; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; OXIDATIVE STRESS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THERAPY EFFECT; THORACIC AORTA; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; CASTRATION; INFLAMMATION; LOX-1; TESTOSTERONE;

ANIMALS; ATHEROSCLEROSIS; HORMONE REPLACEMENT THERAPY; HUMANS; LIPOPROTEINS, LDL; MALE; NF-KAPPA B; SCAVENGER RECEPTORS, CLASS E; SIGNAL TRANSDUCTION; TESTOSTERONE;

EID: 84888438129     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2013.10.003     Document Type: Review

References (69)

1. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., et al. Heart disease and stroke statistics-2010 update. A report from the American Heart Association. Circulation Feb 2010, 21(8):e46-e215. (PMID: 20019324).
2. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev Oct 2004, 84(4):1381-1478.
3. Heinecke J.W. Is the emperor wearing clothes? Clinical trials of vitamin E and the LDL oxidation hypothesis. Arterioscler Thromb Vasc Biol Aug 2001, 21(8):1261-1264.
4. Geng Y.J., Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol Sep 1 2002, 22(9):1370-1380.
5. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature May 19 2011, 473(7347):317-325.
6. de Winther M.P., van Dijk K.W., Havekes L.M., Hofker M.H. Macrophage scavenger receptor class A: a multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol Feb 2000, 20(2):290-297.
7. Langer C., Gansz B., Goepfert C., Engel T., Uehara Y., von Dehn G., et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun Sep 6 2002, 296(5):1051-1057.
8. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., Protter A.A. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem Jun 5 1993, 268(16):11811-11816.
9. Sawamura T., Kume N., Aoyama T., Moriwaki H., Hoshikawa H., Aiba Y., et al. An endothelial receptor for oxidized low-density lipoprotein. Nature Mar 6 1997, 386(6620):73-77.
10. Li S., Guo Y., Zhu P., Yang T. Role of Ox-LDL/LOX-1/NF-kappaB signaling pathway in regulation of atherosclerotic plaque growth by testosterone in male rabbits. Vascul Pharmacol Sep 27 2012.
11. Grady D., Rubin S.M., Petitti D.B., Fox C.S., Black D., Ettinger B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med Dec 15 1992, 117(12):1016-1037.
12. Barrett-Connor E., Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998, 19:55-72.
13. Bourassa P.A., Milos P.M., Gaynor B.J., Breslow J.L., Aiello R.J. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A Sep 17 1996, 93(19):10022-10027.
14. Elhage R., Arnal J.F., Pieraggi M.T., Duverger N., Fievet C., Faye J.C., et al. 17 beta-estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol Nov 1997, 17(11):2679-2684.
15. Marsh M.M., Walker V.R., Curtiss L.K., Banka C.L. Protection against atherosclerosis by estrogen is independent of plasma cholesterol levels in LDL receptor-deficient mice. J Lipid Res May 1999, 40(5):893-900.
16. Hodgin J.B., Krege J.H., Reddick R.L., Korach K.S., Smithies O., Maeda N. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest Feb 2001, 107(3):333-340.
17. Villablanca A.C., Tenwolde A., Lee M., Huck M., Mumenthaler S., Rutledge J.C. 17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice. J Cardiovasc Transl Res Sep 2009, 2(3):289-299.
18. Hodgin J.B., Maeda N. Minireview: estrogen and mouse models of atherosclerosis. Endocrinology Dec 2002, 143(12):4495-4501.
19. Dubey R.K., Jackson E.K., Gillespie D.G., Zacharia L.C., Imthurn B. Catecholamines block the antimitogenic effect of estradiol on human coronary artery smooth muscle cells. J Clin Endocrinol Metab Aug 2004, 89(8):3922-3931.
20. Eckardstein A., Wu F.C. Testosterone and atherosclerosis. Growth Horm IGF Res Aug 2003, 13(Suppl. A):S72-S84.
21. Tan K.C., Shiu S.W., Kung A.W. Alterations in hepatic lipase and lipoprotein subfractions with transdermal testosterone replacement therapy. Clin Endocrinol (Oxf) Dec 1999, 51(6):765-769.
22. von Eckardstein A., Nofer J.R., Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol Jan 2001, 21(1):13-27.
23. Shores M.M., Matsumoto A.M., Sloan K.L., Kivlahan D.R. Low serum testosterone and mortality in male veterans. Arch Intern Med Aug 14-28 2006, 166(15):1660-1665.
24. Laughlin G.A., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab Jan 2008, 93(1):68-75.
25. Hatch N.W., Srodulski S.J., Chan H.W., Zhang X., Tannock L.R., King V.L. Endogenous androgen deficiency enhances diet-induced hypercholesterolemia and atherosclerosis in low-density lipoprotein receptor-deficient mice. Gend Med Oct 2012, 9(5):319-328.
26. Nieschlag E., Nieschlag S., Behre H.M. Lifespan and testosterone. Nature Nov 18 1993, 366(6452):215.
27. Min K.J., Lee C.K., Park H.N. The lifespan of Korean eunuchs. Curr Biol Sep 25 2012, 22(18):R792-R793.
28. Salvayre R., Auge N., Benoist H., Negre-Salvayre A. Oxidized low-density lipoprotein-induced apoptosis. Biochim Biophys Acta Dec 30 2002, 1585(2-3):213-221.
29. Kunjathoor V.V., Febbraio M., Podrez E.A., Moore K.J., Andersson L., Koehn S., et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem Dec 20 2002, 277(51):49982-49988.
30. Ben J., Gao S., Zhu X., Zheng Y., Zhuang Y., Bai H., et al. Glucose-regulated protein 78 inhibits scavenger receptor A-mediated internalization of acetylated low density lipoprotein. J Mol Cell Cardiol Nov 2009, 47(5):646-655.
31. Mitra S., Deshmukh A., Sachdeva R., Lu J., Mehta J.L. Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy. Am J Med Sci Aug 2011, 342(2):135-142.
32. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature Apr 29 1993, 362(6423):801-809.
33. Li A.C., Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat Med Nov 2002, 8(11):1235-1242.
34. Kuge Y., Kume N., Ishino S., Takai N., Ogawa Y., Mukai T., et al. Prominent lectin-like oxidized low density lipoprotein (LDL) receptor-1 (LOX-1) expression in atherosclerotic lesions is associated with tissue factor expression and apoptosis in hypercholesterolemic rabbits. Biol Pharm Bull Aug 2008, 31(8):1475-1482.
35. Ishino S., Mukai T., Kuge Y., Kume N., Ogawa M., Takai N., et al. Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti-LOX-1 antibody: potential agent for imaging of vulnerable plaque. J Nucl Med Oct 2008, 49(10):1677-1685.
36. Mehta J.L., Li D.Y. Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells. Biochem Biophys Res Commun Jul 30 1998, 248(3):511-514.
37. Li D., Mehta J.L. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol Apr 2000, 20(4):1116-1122.
38. Kanters E., Pasparakis M., Gijbels M.J., Vergouwe M.N., Partouns-Hendriks I., Fijneman R.J., et al. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest Oct 2003, 112(8):1176-1185.
39. Cao Y., Zhou X., Liu H., Zhang Y., Yu X., Liu C. The NF-kappaB pathway: regulation of the instability of atherosclerotic plaques activated by Fg, Fb, and FDPs. Mol Cell Biochem 2013, 383(1-2):29-37. (PMID:23839109).
40. Monaco C., Paleolog E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res Mar 1 2004, 61(4):671-682.
41. Brand K., Page S., Rogler G., Bartsch A., Brandl R., Knuechel R., et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest Apr 1 1996, 97(7):1715-1722.
42. Robbesyn F., Salvayre R., Negre-Salvayre A. Dual role of oxidized LDL on the NF-kappaB signaling pathway. Free Radic Res Jun 2004, 38(6):541-551.
43. Xu S., Ogura S., Chen J., Little P.J., Moss J., Liu P. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci Aug 2013, 70(16):2859-2872.
44. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol Dec 2009, 1(6):a001651.
45. Cominacini L., Pasini A.F., Garbin U., Davoli A., Tosetti M.L., Campagnola M., et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem Apr 28 2000, 275(17):12633-12638.
46. Ryoo S., Bhunia A., Chang F., Shoukas A., Berkowitz D.E., Romer L.H. OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling. Atherosclerosis Feb 2011, 214(2):279-287.
47. Shi Y., Cosentino F., Camici G.G., Akhmedov A., Vanhoutte P.M., Tanner F.C., et al. Oxidized low-density lipoprotein activates p66Shc via lectin-like oxidized low-density lipoprotein receptor-1, protein kinase C-beta, and c-Jun N-terminal kinase kinase in human endothelial cells. Arterioscler Thromb Vasc Biol Sep 2011, 31(9):2090-2097.
48. Cominacini L., Rigoni A., Pasini A.F., Garbin U., Davoli A., Campagnola M., et al. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem Apr 27 2001, 276(17):13750-13755.
49. Xu X., Gao X., Potter B.J., Cao J.M., Zhang C. Anti-LOX-1 rescues endothelial function in coronary arterioles in atherosclerotic ApoE knockout mice. Arterioscler Thromb Vasc Biol Apr 2007, 27(4):871-877.
50. Mehta J.L., Sanada N., Hu C.P., Chen J., Dandapat A., Sugawara F., et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res Jun 8 2007, 100(11):1634-1642.
51. Hu C., Dandapat A., Sun L., Chen J., Marwali M.R., Romeo F., et al. LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet. Cardiovasc Res Jul 15 2008, 79(2):287-293.
52. Eto H., Miyata M., Kume N., Minami M., Itabe H., Orihara K., et al. Expression of lectin-like oxidized LDL receptor-1 in smooth muscle cells after vascular injury. Biochem Biophys Res Commun Mar 10 2006, 341(2):591-598.
53. Kataoka H., Kume N., Miyamoto S., Minami M., Morimoto M., Hayashida K., et al. Oxidized LDL modulates Bax/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol Jun 2001, 21(6):955-960.
54. Aoyama T., Chen M., Fujiwara H., Masaki T., Sawamura T. LOX-1 mediates lysophosphatidylcholine-induced oxidized LDL uptake in smooth muscle cells. FEBS Lett Feb 11 2000, 467(2-3):217-220.
55. Ogura S., Kakino A., Sato Y., Fujita Y., Iwamoto S., Otsui K., et al. Lox-1: the multifunctional receptor underlying cardiovascular dysfunction. Circ J Nov 2009, 73(11):1993-1999.
56. Chen X.P., Zhang T.T., Du G.H. Lectin-like oxidized low-density lipoprotein receptor-1, a new promising target for the therapy of atherosclerosis?. Cardiovasc Drug Rev Summer 2007, 25(2):146-161.
57. Mehta J.L., Khaidakov M., Hermonat P.L., Mitra S., Wang X., Novelli G., et al. LOX-1: a new target for therapy for cardiovascular diseases. Cardiovasc Drugs Ther Oct 2011, 25(5):495-500.
58. Lu J., Mitra S., Wang X., Khaidakov M., Mehta J.L. Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis. Antioxid Redox Signal Oct 15 2011, 15(8):2301-2333.
59. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation Jan 18 2000, 101(2):207-213.
60. Draude G., Hrboticky N., Lorenz R.L. The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Biochem Pharmacol Feb 15 1999, 57(4):383-386.
61. Li D.Y., Chen H.J., Mehta J.L. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res Oct 2001, 52(1):130-135.
62. Hofnagel O., Luechtenborg B., Eschert H., Weissen-Plenz G., Severs N.J., Robenek H. Pravastatin inhibits expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in Watanabe heritable hyperlipidemic rabbits: a new pleiotropic effect of statins. Arterioscler Thromb Vasc Biol Mar 2006, 26(3):604-610.
63. Kang B.Y., Wang W., Palade P., Sharma S.G., Mehta J.L. Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. J Cardiovasc Pharmacol Oct 2009, 54(4):327-334.
64. Sun Y., Chen X. Ox-LDL-induced LOX-1 expression in vascular smooth muscle cells: role of reactive oxygen species. Fundam Clin Pharmacol Oct 2011, 25(5):572-579.
65. Li L., Sawamura T., Renier G. Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res Apr 16 2004, 94(7):892-901.
66. Xu S., Liu Z., Huang Y., Le K., Tang F., Huang H., et al. Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-kappaB activation. Transl Res Aug 2012, 160(2):114-124.
67. Gao S., Liu Z., Li H., Little P.J., Liu P., Xu S. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis Jan 2012, 220(1):3-10.
68. Xu S., Little P.J., Lan T., Huang Y., Le K., Wu X., et al. Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. Arch Biochem Biophys Nov 2011, 515(1-2):72-79.
69. Qiu Y., Yanase T., Hu H., Tanaka T., Nishi Y., Liu M., et al. Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development. Endocrinology Jul 2010, 151(7):3307-3316.